Methods for screening and identifying compounds

Abstract

The present invention relates to methods for assessing enzyme activity utilizing a phase partition system. In addition, the present invention also relates to methods for screening and identifying compounds that may be used, for example, for the treatment of diabetes, diabetes-related disorders, obesity, cardiovascular disease, cancer, and other diseases or disorders, using this phase partition system.

1 . (canceled)  
   
   
       2 . (canceled)  
   
   
       3 . (canceled)  
   
   
       4 . (canceled)  
   
   
       5 . (canceled)  
   
   
       6 . (canceled)  
   
   
       7 . (canceled)  
   
   
       8 . (canceled)  
   
   
       9 . (canceled)  
   
   
       10 . (canceled)  
   
   
       11 . (canceled)  
   
   
       12 . (canceled)  
   
   
       13 . (canceled)  
   
   
       14 . (canceled)  
   
   
       15 . (canceled)  
   
   
       16 . (canceled)  
   
   
       17 . (canceled)  
   
   
       18 . (canceled)  
   
   
       19 . (canceled)  
   
   
       20 . (canceled)  
   
   
       21 . (canceled)  
   
   
       22 . (canceled)  
   
   
       23 . (canceled)  
   
   
       24 . (canceled)  
   
   
       25 . (canceled)  
   
   
       26 . (canceled)  
   
   
       27 . (canceled)  
   
   
       28 . (canceled)  
   
   
       29 . (canceled)  
   
   
       30 . (canceled)  
   
   
       31 . A method of treating diabetes, diabetes-related disorders, obesity, cardiovascular disease, and cancer comprising administering to a mammal a therapeutically effective amount of a compound identified by the method comprising 
 combining an enzyme, radiolabeled substrate(s) and test compounds, adding a phase-partition scintillation fluid: incubating the reaction for at least two hours: and detecting enzyme activity,    wherein said reaction does not require mixing following addition of the phase-partition scintillation fluid and wherein said reaction is conducted in a single reaction vessel.    
   
   
       32 . The method of  claim 31 , wherein said compound is administered in combination with one or more pharmaceutical agents.  
   
   
       33 . A pharmaceutical composition comprising a compound identified by the method comprising 
 combining an enzyme, radiolabeled substrate(s) and test compounds: adding a phase-partition scintillation fluid: incubating the reaction for at least two hours: and detecting enzyme activity,    wherein said reaction does not require mixing following addition of the phase-partition scintillation fluid and wherein said reaction is conducted in a single reaction vessel, in combination with a pharmaceutically acceptable carrier.    
   
   
       34 . The pharmaceutical composition of  claim 33 , further comprising one or more pharmaceutical agents.